These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37433433)

  • 21. Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
    Hodgson D; Lai Z; Dearden S; Barrett JC; Harrington EA; Timms K; Lanchbury J; Wu W; Allen A; Senkus E; Domchek SM; Robson M
    Ann Oncol; 2021 Dec; 32(12):1582-1589. PubMed ID: 34500047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?
    van Wijk LM; Nilas AB; Vrieling H; Vreeswijk MPG
    Expert Rev Mol Diagn; 2022 Feb; 22(2):185-199. PubMed ID: 34913794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of DNA Helicase Genes Was Correlated with Homologous Recombination Deficiency in Breast Cancer.
    Long M; Liu H; Wu J; Wang S; Liao X; Liu Y; Hu T
    Comput Math Methods Med; 2022; 2022():5508301. PubMed ID: 35855837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcomes and longitudinal circulating tumor DNA changes after treatment with nivolumab and olaparib in immunotherapy relapsed melanoma with detected homologous recombination deficiency.
    Khaddour K; Ansstas M; Ansstas G
    Cold Spring Harb Mol Case Stud; 2021 Oct; 7(5):. PubMed ID: 34667064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency.
    Li W; Gao L; Yi X; Shi S; Huang J; Shi L; Zhou X; Wu L; Ying J
    Genomics Proteomics Bioinformatics; 2023 Oct; 21(5):962-975. PubMed ID: 36791952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of HRD functional phenotype impedes immunotherapy and can be reversed by HDAC inhibitor in ovarian cancer.
    Yang D; Huang FX; Wei W; Li QQ; Wu JW; Huang Y; Li ZL; Zhang HL; Li X; Yuan QE; Chen QS; Feng GK; Rong D; Li JD; Zhu XF
    Int J Biol Sci; 2023; 19(6):1846-1860. PubMed ID: 37063431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
    Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
    Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of homologous recombination deficiency from routine histology with attention-based multiple instance learning in nine different tumor types.
    Loeffler CML; El Nahhas OSM; Muti HS; Carrero ZI; Seibel T; van Treeck M; Cifci D; Gustav M; Bretz K; Gaisa NT; Lehmann KV; Leary A; Selenica P; Reis-Filho JS; Ortiz-Bruechle N; Kather JN
    BMC Biol; 2024 Oct; 22(1):225. PubMed ID: 39379982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors.
    Lahiguera Á; Hyroššová P; Figueras A; Garzón D; Moreno R; Soto-Cerrato V; McNeish I; Serra V; Lazaro C; Barretina P; Brunet J; Menéndez J; Matias-Guiu X; Vidal A; Villanueva A; Taylor-Harding B; Tanaka H; Orsulic S; Junza A; Yanes O; Muñoz-Pinedo C; Palomero L; Pujana MÀ; Perales JC; Viñals F
    EMBO Mol Med; 2020 Jun; 12(6):e11217. PubMed ID: 32400970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.
    Yi T; Feng Y; Sundaram R; Tie Y; Zheng H; Qian Y; You D; Yi T; Wang P; Zhao X
    Int J Cancer; 2019 Sep; 145(5):1209-1220. PubMed ID: 30666631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients.
    Chen Y; Zheng X; Lin J; Gao X; Xiong J; Liu J; Fei Z; Chen C
    Oral Oncol; 2022 May; 128():105860. PubMed ID: 35428026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of homologous recombination deficiency from Oncomine Comprehensive Assay Plus correlating with SOPHiA DDM HRD Solution.
    Kang J; Na K; Kang H; Cho U; Kwon SY; Hwang S; Lee A
    PLoS One; 2024; 19(3):e0298128. PubMed ID: 38527014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance to Poly (ADP-Ribose) Polymerase Inhibitors (PARPi): Mechanisms and Potential to Reverse.
    Washington CR; Moore KN
    Curr Oncol Rep; 2022 Dec; 24(12):1685-1693. PubMed ID: 36346509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamic immunoediting by macrophages in homologous recombination deficiency-stratified pancreatic ductal adenocarcinoma.
    Hong WF; Zhang F; Wang N; Bi JM; Zhang DW; Wei LS; Song ZT; Mills GB; Chen MM; Li XX; Du SS; Yu M
    Drug Resist Updat; 2024 Sep; 76():101115. PubMed ID: 39002266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity.
    Smeby J; Kryeziu K; Berg KCG; Eilertsen IA; Eide PW; Johannessen B; Guren MG; Nesbakken A; Bruun J; Lothe RA; Sveen A
    EBioMedicine; 2020 Sep; 59():102923. PubMed ID: 32799124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pan-cancer landscape of homologous recombination deficiency.
    Nguyen L; W M Martens J; Van Hoeck A; Cuppen E
    Nat Commun; 2020 Nov; 11(1):5584. PubMed ID: 33149131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biomarkers for Homologous Recombination Deficiency in Cancer.
    Hoppe MM; Sundar R; Tan DSP; Jeyasekharan AD
    J Natl Cancer Inst; 2018 Jul; 110(7):704-713. PubMed ID: 29788099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
    Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
    Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Homologous Recombination Repair Deficiency: An Overview for Pathologists.
    Doig KD; Fellowes AP; Fox SB
    Mod Pathol; 2023 Mar; 36(3):100049. PubMed ID: 36788098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
    Kim DS; Camacho CV; Kraus WL
    Exp Mol Med; 2021 Jan; 53(1):42-51. PubMed ID: 33487630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.